Drugs / TX103
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07231081 | Oct 2025 → Dec 2027 expected | cancer | Tcelltech Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06482905 | Sep 2024 → Sep 2026 overdue | glioma | Tcelltech Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TX103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231081 ↗ |
| Action | Deplete | “This therapy is designed to recognize and kill TX103-expressing malignant cells.” NCT07231081 ↗ |
| Modality | Cell therapy | “CAR-T cell therapy” NCT06482905 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT07231081 ↗ |